RT Journal Article
SR Electronic
T1 Qualitative Changes in the SARS-CoV-2 Antibody Response in the Post-Infection Phase Impact the estimates of infections in Population-Based Seroprevalence Studies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.14.20153536
DO 10.1101/2020.07.14.20153536
A1 Fenwick, Craig
A1 Croxatto, Antony
A1 Coste, Alix T.
A1 Pojer, Florence
A1 André, Cyril
A1 Pellaton, Céline
A1 Farina, Alex
A1 Campos, Jérémy
A1 Hacker, David
A1 Lau, Kelvin
A1 Bosch, Berend-Jan
A1 Nussle, Semira Gonseth
A1 Bochud, Murielle
A1 D’Acremont, Valerie
A1 Trono, Didier
A1 Greub, Gilbert
A1 Pantaleo, Giuseppe
YR 2020
UL http://medrxiv.org/content/early/2020/07/17/2020.07.14.20153536.abstract
AB In the present study, we have determined SARS-CoV-2-specific antibody responses in a cohort of 96 individuals during the acute phase of infection and in a cohort of 578 individuals enrolled in a seroprevalence population study in Switzerland including three groups, i.e. subjects with previous RT-PCR confirmed SARS-CoV-2 infections (n=90), ‘positive patient contact’ (n=177) and ‘random selected subjects’ (n=311). Six serological assays detecting predominantly IgG antibodies targeting either the Spike (S) and/or the nucleocapsid (N) proteins were used including also a Luminex based assay using an S protein in its native trimeric form. Antibody responses against the S and/or the N proteins were equally sensitive in the acute infection phase although differences in sensitivity (range 83 to 97% 16-33 days post-initial symptoms) were observed between the different assays and the Luminex S protein trimer assay was the most sensitive. Interestingly, antibody responses against the N protein appear to wane in the post-infection phase of the infection while those against the S protein persist over time, as indicated by the drop in sensitivity of the assays targeting the N protein (sensitivity range 71-77%). Assays detecting anti-N IgG antibodies may substantially underestimate the proportion of SARS-CoV-2 infections in the groups of ‘patient positive contacts’, i.e. 10.9 to 32.2% reduction (P<0.05-<0.0001) and in the ‘random selected’ general population, i.e. up to 45% reduction (P<0.05). The overall reduction in seroprevalence for the total cohort ranged from 9.4 to 31% (P<0.0009-<0.0001). Of note, the assay using the S protein in its native trimer form was more sensitive as compared to those using monomeric S proteins.These results indicate that assays targeting the S protein, ideally the trimeric form, should be implemented as reference test to estimate SARS-CoV-2 infections in seroprevalence population studies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for this project was provided through the Lausanne University Hospital, through the Swiss Vaccine research institute and through the Coronavirus Accelerated R&D in Europe (CARE) IMI project.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Commission ethique du Canton de Vaud (CER-VD) stated that authorization was not requiredAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon request